Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer
NCT ID: NCT06232122
Last Updated: 2024-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
45 participants
INTERVENTIONAL
2022-08-01
2028-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective Cohort Study of 68ga-FAPI-pet-ct Versus FDG-pet-ct for Ovarian Cancer
NCT05824247
Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence
NCT05856409
Clinical Study of 18F-FAPI-RGD in Ovarian Cancer
NCT06614062
68Ga-FAPI-04 and 18F-FDG PET/CT in Patients With Epithelial Ovarian Cancer: Compared With Histological Findings
NCT04504110
18F-FSPG PET/CT Imaging in Patients With Cancers
NCT03144622
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
68Ga-FAPI ,PET/CT
Inject 68Ga-FAPI and then perform PET/CT scan.
68Ga-FAPI-46
Intravenous injection of one dosage of 2 mCi 68Ga-FAPI-46
18F-FDG
Intravenous injection of one dosage of 5-10mCi 18F-FDG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
68Ga-FAPI-46
Intravenous injection of one dosage of 2 mCi 68Ga-FAPI-46
18F-FDG
Intravenous injection of one dosage of 5-10mCi 18F-FDG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 30 and 80
* Elevation of serum CA125 value above the normal range (\>35 U/mL) or doubling of serum CA125 value within the normal range
* ECOG performance status grade 0 or 1 and willing to receive further therapy if disease recurrence is confirmed
* Willing to enter this prospective study with signed informed consent form
Exclusion Criteria
* Patients who are pregnant or lactating
* Patients with fasting fingerstick glucose level higher than 200 mg/dl
* Known allergic reactions to components of the radiopharmaceutical solutions for intravenous injection for 68Ga-FAPI-46 or 18F-FDG imaging studies
* Patients who are incapable of lying still for 30 minutes to receive the PET/CT scan as assessed by investigators
30 Years
80 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chang Gung Memorial Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Feng-Yuan Liu, MD
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chang-Gung Memorial Hospital, Linkou Branch
Taoyuan, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
202102208A0
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.